Literature DB >> 14601560

Cell death in human acute myelogenous leukemic cells induced by pyrrolidinedithiocarbamate.

L Malaguarnera1, M R Pilastro, R DiMarco, C Scifo, M Renis, M C Mazzarino, A Messina.   

Abstract

Pyrrolidinedithiocarbamate (PDTC) is a metal chelating compound, which exerts both pro-apoptotic effect and pro-oxidant activity on many cells. Our objective was to investigate whether PDTC was able to interfere with apoptotic process in leukemic and normal bone marrow CD34+ cells. Since hematopoietic growth factors stimulate growth and differentiation and prevent apoptosis, we therefore studied the effect of growth factors pretreatment, such as interleukin-3 and granulocyte-macrophage colony stimulating factor, in human myeloid CD34+ cells to evaluate whether they protect the cells from the apoptotic action of PDTC. We revealed that PDTC exerted an apoptotic effect in leukemic CD34+ cells. This effect was dependent on the ability of this compound to generate the oxidation of cellular glutathion to its disulphide and consequently to induce an intracellular oxidative stress. Hematopoietic growth factors did not protect cells from apoptosis induced by previous treatment with PDTC. The ability of PDTC to induce apoptosis was restricted to acute myelogenous leukaemia CD34+ cells, since normal CD34+cells were insensitive to the pro-oxidant effect of PDTC. These findings imply that normal cells are equipped with mechanisms by which they respond differently to PDTC effects with respect to leukemic cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14601560     DOI: 10.1023/a:1025550726803

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  8 in total

1.  A novel dithiocarbamate analogue with potentially decreased ALDH inhibition has copper-dependent proteasome-inhibitory and apoptosis-inducing activity in human breast cancer cells.

Authors:  Fei Wang; Shumei Zhai; Xiaojun Liu; Liwen Li; Shirley Wu; Q Ping Dou; Bing Yan
Journal:  Cancer Lett       Date:  2010-10-29       Impact factor: 8.679

2.  NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells.

Authors:  Jiangbing Zhou; Hao Zhang; Peihua Gu; Jining Bai; Joseph B Margolick; Ying Zhang
Journal:  Breast Cancer Res Treat       Date:  2007-10-27       Impact factor: 4.872

3.  Pyrrolidine dithiocarbamate-zinc(II) and -copper(II) complexes induce apoptosis in tumor cells by inhibiting the proteasomal activity.

Authors:  Vesna Milacic; Di Chen; Lorena Giovagnini; Alejandro Diez; Dolores Fregona; Q Ping Dou
Journal:  Toxicol Appl Pharmacol       Date:  2008-03-28       Impact factor: 4.219

Review 4.  New applications of old metal-binding drugs in the treatment of human cancer.

Authors:  Sara M Schmitt; Michael Frezza; Qing Ping Dou
Journal:  Front Biosci (Schol Ed)       Date:  2012-01-01

5.  Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells.

Authors:  Kenyon G Daniel; Di Chen; Shirley Orlu; Qiuzhi Cindy Cui; Fred R Miller; Q Ping Dou
Journal:  Breast Cancer Res       Date:  2005-09-20       Impact factor: 6.466

6.  A Central Role for JNK/AP-1 Pathway in the Pro-Oxidant Effect of Pyrrolidine Dithiocarbamate through Superoxide Dismutase 1 Gene Repression and Reactive Oxygen Species Generation in Hematopoietic Human Cancer Cell Line U937.

Authors:  Humberto Riera; Valéry Afonso; Pascal Collin; Abderrahim Lomri
Journal:  PLoS One       Date:  2015-05-21       Impact factor: 3.240

Review 7.  Therapeutic potential of dithiocarbamate supported gold compounds.

Authors:  Christian K Adokoh
Journal:  RSC Adv       Date:  2020-01-16       Impact factor: 4.036

8.  Activation of nuclear factor-κB in the brain after experimental subarachnoid hemorrhage and its potential role in delayed brain injury.

Authors:  Wan-Chun You; Chun-Xi Wang; Yun-Xi Pan; Xin Zhang; Xiao-Ming Zhou; Xiang-Sheng Zhang; Ji-Xin Shi; Meng-Liang Zhou
Journal:  PLoS One       Date:  2013-03-25       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.